BioGenes shows latest HCP and ELISA testing tools at BioProcessing Summit

BioGenes shows latest HCP and ELISA testing tools at BioProcessing Summit


Press Release | BioGenes GmbH

JULY 31, 2018

Berlin, Germany: – Leading force in host cell protein (HCP) assay development, BioGenes GmbH, will present its latest services and products in Boston at the upcoming 10th Anniversary BioProcessing Summit.

BioGenes will be an exhibitor at the event with a stand at Booth 414 at the Sheraton Boston, the third year running it has been an exhibitor and poster at the BioProcessing meeting.

The BioGenes team will be represented by the Strategic Product and Innovation Managers Michael Kirchner and Dr. Yvonne Haberkorn.

HCP and ELISA testing

The BioGenes display will highlight advances made in its host cell protein (HCP) kits and ELISA testing services as part of a complete panel of services and products for quality control purposes of biological production. These include custom antibody development (pAbs, mAbs, anti-IDs), custom ELISA development and kit production, HCP assays, analytical services and feasibility studies.

Biological production trends

“We are delighted to be returning to BioProcessing Summit, having previously attended the 2016 and 2017 events,” said BioGenes Marketing & Sales Director, Dagmar Schwertner-Knoll.

“The annual BioProcessing Summit provides a superb platform for networking and sharing insights on techniques and trends in biological production and quality control,” she commented.

“This is the place to hear from company decision makers and representatives of the regulatory authorities,” Ms. Dagmar Schwertner-Knoll added.

About BioGenes GmbH

BioGenes GmbH (BioGenes) is an acknowledged global leader in host cell protein (HCP) assay development and a recognized partner of pharmaceutical companies all over the world. The Berlin-based company specializes in highly sophisticated and customized antibody and immunoassay development and is an experienced and reliable partner for process development improvements in all areas of quality control, diagnostics and drug discovery.

BioGenes is known as a trusted and experienced expert in immunoassay, 2D electrophoresis and antibody development with a business strategy focused on driving forward innovations for customers and building new strategic partnerships aimed at cementing its market leadership in host cell assay development.

BioGenes was founded in 1992 by Dr. Alexander Knoll (Managing Director) and Dr. Sergej Ovodov (Scientific Director), who are now sole owners following a management buyout in October 2015. Headquartered in Berlin, the company has a workforce numbering more than 50 people, most of them scientists.

The company maintains long-term relationships with research institutes, universities and biotech and pharmaceutical companies, including eight of the ten largest pharmaceutical companies in the world.

About BioProcessing Summit 2018

The Bioprocessing Summit convenes more than 1,000 international bioprocess professionals to share practical solutions for today’s bioprocess challenges.

The tenth anniversary BioProcessing Summit 2018 is a five -day event opening August 13 at the Sheraton Hotel, Boston, MA.

Since foundation the event has grown to include 17 distinct conferences with week-long programs on upstream and downstream processing, analytical development and quality, formulation and stability, cell and gene therapy production, and manufacturing.

Alongside the conference program, the Summit hosts short courses and training seminars that provide in-depth coverage of critical bioprocess topics.

The event is organized by CHI with more information available at:

Media Contact

Dagmar Schwertner-Knoll, Marketing & Sales Director, BioGenes GmbH
Tel: +49 30 6576 2396


Click on BioGenes at BioProcessing Summit 2018 for more information.
Click on BioGenes to contact the company directly.

Supplier Information
Supplier: BioGenes GmbH
Address: Koepenicker Str. 325, D-12555 Berlin, Germany
Tel: +49 30 6576 2396
Fax: +49 30 6576 2397

Comments are closed.